Comparative Evaluation of the Efficacy and Safety of Brimonidine Generics in Glaucoma Therapy
Open Access
- 28 December 2023
- journal article
- research article
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 20 (4) , 761-766
Abstract
Glaucoma is a chronic neurodegenerative disease that eventually leads to irreversible blindness. The main risk factor for the development and progression of glaucoma is elevated IOP. In cases where the use of prostaglandin analogues is limited, brimonidine is the most rational choice as initial therapy. It is the only molecule that both reduces aqueous humor production and enhances uveoscleral outflow. The use of several hypotensive drugs for a long time can lead to pronounced changes in the tissues of the anterior segment of the eye. In this case, there are complaints characteristic of the dry eye syndrome. The aggravation of this condition can affect the adherence of patients to treatment and worsen the course of the disease. Therefore, it is important to prescribe hypotensive drugs that have a sufficient hypotensive effect with a good safety profile. Purpose. To evaluate the efficacy and safety of Brimonidine SZ in combination therapy for glaucoma after changing the hypotensive regimen. Patients and methods. The study was conducted in a group of 50 patients (50 eyes) with initial or advanced drug-compensated primary open-angle glaucoma (mean age 64.8 years), among them there were 27 (54 %) women and 23 (46 %) men. In patients included in the study, brimonidine 0.15 % or 0.2 % was replaced with Brimonidine SZ as part of combination hypotensive therapy. To analyze the results obtained, data on corneal-compensated IOP, the degree of corneal staining with fluorescein, assessments of conjunctival hyperemia, indicators of the OSDI questionnaire and the level of adherence to treatment at the initial visit, as well as 1 and 3 months after changing the hypotensive regimen, were compared. Results. There were no statistically significant differences in the level of IOP at different times after changing the hypotensive regimen. Objective indicators of the state of the tissues of the anterior surface of the eye did not change. According to the results of the evaluation of the main signs of dry eye syndrome (OSDI) and the degree of adherence of patients to treatment, no significant changes were found either. Conclusion. Brimonidine SZ has a similar hypotensive efficacy with brimonidine 0.15 % and 0.2 % as part of combination hypotensive therapy. The safety profile of Brimonidine SZ is comparable to analogues, which allows us to consider this drug as a possible alternative when choosing hypotensive therapy.Keywords
This publication has 15 references indexed in Scilit:
- Brimonidine as an additional treatment for moderate glaucomaRussian Journal of Clinical Ophthalmology, 2021
- Sustainable treatment of glaucoma patients with cardiovascular diseasesRussian Ophthalmological Journal, 2020
- The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional testsRussian Annals of Ophthalmology, 2020
- Ophthalmic risk factors for primary open angle glaucomaRussian Journal of Clinical Ophthalmology, 2019
- Alpha-adrenergic receptor agonists in terms of modern views on glaucoma monitoring and treatmentRussian Journal of Clinical Ophthalmology, 2019
- Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safetyRussian Annals of Ophthalmology, 2019
- Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertensionAdvances in Therapy, 2007
- Brimonidine and Timolol Fixed-Combination Therapy Versus Monotherapy: A 3-Month Randomized Trial in Patients with Glaucoma or Ocular HypertensionJournal of Ocular Pharmacology and Therapeutics, 2005
- Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye TestsCornea, 2003
- Allergic reactions to brimonidine in patients treated for glaucomaCanadian Journal of Ophthalmology, 2002